A detailed history of State Street Corp transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 6,347,321 shares of CRBU stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,347,321
Previous 5,119,666 23.98%
Holding current value
$18.3 Million
Previous $29.3 Million 11.22%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.82 - $8.26 $5.92 Million - $10.1 Million
1,227,655 Added 23.98%
6,347,321 $32.6 Million
Q4 2023

Feb 14, 2024

SELL
$3.58 - $6.25 $836,728 - $1.46 Million
-233,723 Reduced 4.37%
5,119,666 $29.3 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $17.5 Million - $34.9 Million
4,283,243 Added 400.25%
5,353,389 $25.6 Million
Q2 2023

Aug 14, 2023

SELL
$4.04 - $5.47 $9.23 Million - $12.5 Million
-2,285,146 Reduced 68.11%
1,070,146 $4.55 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $7.78 $672,515 - $1.22 Million
156,399 Added 4.89%
3,355,292 $17.8 Million
Q4 2022

Feb 14, 2023

BUY
$5.57 - $11.01 $4.48 Million - $8.85 Million
803,423 Added 33.54%
3,198,893 $20.1 Million
Q3 2022

Nov 15, 2022

BUY
$5.34 - $12.79 $8.53 Million - $20.4 Million
1,597,870 Added 200.33%
2,395,470 $25.3 Million
Q2 2022

Aug 15, 2022

BUY
$5.1 - $9.74 $278,347 - $531,589
54,578 Added 7.35%
797,600 $4.33 Million
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $2.78 Million - $5.06 Million
330,074 Added 79.93%
743,022 $6.82 Million
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $1.89 Million - $3.01 Million
129,359 Added 45.61%
412,948 $6.23 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $4.47 Million - $8.59 Million
283,589 New
283,589 $6.77 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $175M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.